Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 30, 2020
Summit, NJ 30 Jul 2020 Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season Seqirus is...
-
Jun 8, 2020
This news release is intended for medical, pharmaceutical industry and business media Maidenhead, UK 08 Jun 2020 The European Commission has today given regulatory approval for the first...
-
Jun 5, 2020
Oslo, Melbourne and Brisbane 05 Jun 2020 CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate CEPI and CSL will share costs...
-
Apr 6, 2020
GLOBAL PLASMA LEADERS COLLABORATE TO ACCELERATE DEVELOPMENT OF POTENTIAL COVID-19 HYPERIMMUNE THERAPY −Partnership brings together world-leading plasma companies to focus on developing and...
-
Apr 3, 2020
Safeguarding our people and communities remains our top priority. 03 Apr 2020 As the COVID-19 pandemic evolves, we are continuing to take steps to ensure the health and safety of our workforce and...
-
Mar 31, 2020
This news release is intended for medical and pharmaceutical trade media and financial media only 31 Mar 2020 Seqirus, a global leader in influenza prevention, today announced that its adjuvanted...
-
Mar 23, 2020
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. By Anthony Farina – Chief Communications Officer, CSL Limited | 23 Mar 2020...
-
Dec 11, 2019
Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of...
-
Dec 9, 2019
Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine...
-
Sep 26, 2019
The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative...